<DOC>
	<DOCNO>NCT01100177</DOCNO>
	<brief_summary>Sunitinib seem promising treatment objective proposal : evaluate clinical activity Sunitinib first line therapy patient measurable disease evaluate safety Sunitinib radiation therapy .</brief_summary>
	<brief_title>Study Sunitinib Before During Radiotherapy Newly Diagnosed Biopsy-only Glioblastoma Patients</brief_title>
	<detailed_description>Sunitinib ( SU 11248 ) small molecule good oral bioavailability inhibit multiple receptor tyrosine kinase ( RTKs ) express diverse tumour cell : VEGFR , PDGFR , KIT , FLT3 endothelium , pericytes , stroma VEGFR , PDGFR . It potential inhibit directly growth multiple tumour type inhibition multiple target act negatively antiangiogenesis . Glioblastoma ( GB ) frequent brain tumour . Standard treatment surgical resection radiation therapy Temozolomide . But patient afford biopsy lesion due location eloquent area tumour multifocality , n't get benefit treatment median survival best case 9 month . These patient constitute 30 % Glioblastomas . Clinical trial set required patient treat immediately biopsy prevent neurological deterioration . These patient ideal test new promising therapy . Their survival similar recurrent patient . The evaluation response easier 's possible avoid confound post-surgical change interfere evaluation treatment efficacy term tumour size reduction.. Furthermore , neo adjuvant treatment radiotherapy show worsen survival . Glioblastoma tumour rich molecular abnormality . PDGFRs important growth signal pathway neoangiogenesis gliomas . PDGF ligands PDGFR-alfa express human glioma , PDGFR-beta express glioma cell tumor endothelial cell , PDFGR-α express human glioma . Imatinib mesylate exhibit antiglioma activity preclinical study , sensitize glioma cell radiation injury , combine hydroxyurea show promising result recurrent set . Moreover gliomas among angiogenic cancer . VEGF/VEGFR-2 prominent angiogenic signal pathway . Its inhibition either neutralize anti-VEGF antibody , anti-sense VEGF construct , expression dominant-negative mutant form VEGFR-2 ( specific small molecule inhibitor VEGFR-2 tyrosine kinase ) neutralize anti-VEGFR-2 antibody result suppression experimental malignant glioma growth . VEGF focus development glioma-targeted therapy . Recently Bevacizumab show active phase II study . For reason , Sunitinib seem promising treatment fo The objective proposal evaluate clinical activity Sunitinib first line therapy patient measurable disease evaluate safety Sunitinib radiation therapy .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Patients glioblastoma , non resectable , biopsy surgical treatment . 2 . Measurable disease contrast capture 2cm 3 . Stable dos DXM week inclusion 4 . Performance status 012 5 . Age &lt; 75 year 6 . MMS &gt; 25/30 7 . Barthel index &gt; 50 % 8 . Surgical incision must heal inclusion 9 . Basal MRI do 3 week begin treatment specified condition protocol . 10 . FEVI &gt; 50 % 11 . Suitable medullar reserve ( neutrophils _2000x109/L , platelet _ 100x109/L , Haemoglobin _ 10 g/dl . ) 12 . Not previous chemotherapy radiation treatment . 13 . Creatinin &lt; 1,5 time superior standard limit laboratory charge analysis . 14 . Serum Bilirubin &lt; 1 , 5/ULN , SGOT SGPT _ 2,5 time superior standard limit laboratory charge analysis . Serum alkaline phosphatase &lt; 3/ULN . 15 . Effective contraception method patient couple . 16 . Informed consent . 1 . Previous radiation chemotherapy glioma´s treatment . 2 . Less 5 year time previous infiltrant neoplasia 3 . Serious Cerebral haemorrhage biopsy 4 . Anticomital treatment induct / inhibit CYP3A4 enzyme : fenitoin , carbamacepzin , phenobarbitone drug interact sunitinib metabolism could replace another drug without interaction Sunitinib . 5 . Pregnancy lactation . 6 . Active control cardiovascular disease hypertension , angor instable , cardiac congestive failure IInd degree ( NYHA ) , cardiac arrhythmia , previous myocardium heart attack , 1 year randomization 7 . Currently treatment establish therapeutic dos derivated anticoagulant coumarin ( coumarin , warfarin ) week begin sunitinib . The administration heparins low molecular weight TVP 's control allow 8 . Patient TVP 9 . HTA high value 150/100 controllable antihypertensive standard drug 10 . Not healed scar , sores bone fracture 11 . Hemorrhagic diathesis coagulate illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Patients non resectable Glioblastoma</keyword>
	<keyword>biopsy surgical treatment</keyword>
</DOC>